Fatty acid amide hydrolase but not monoacyl glycerol lipase controls cell death induced by the endocannabinoid 2-arachidonoyl glycerol in hepatic cell populations

Biochemical and Biophysical Research Communications

Volumn 437, Issue 1, 2013, Pages 48-54

  Siegmund, Sören V ^a,b   Wojtalla, Alexandra ^a,b   Schlosser, Monika ^a   Zimmer, Andreas ^a   Singer, Manfred V ^b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

2 Arachidonoyl glycerol; Cell death; Endocannabinoids; Fatty acid amide hydrolase; Hepatic stellate cells; Monoacylglycerol lipase

Indexed keywords

2 ARACHIDONOYL GLYCEROL; ACYLGLYCEROL LIPASE; ANANDAMIDE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENDOCANNABINOID; FATTY ACID AMIDASE; GLUTATHIONE; GLYCEROL; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL POPULATION; CONTROLLED STUDY; ENZYME DEGRADATION; LIVER CELL; LIVER FIBROSIS; LIVER INJURY; LIVER PROTECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STELLATE CELL;

2-ARACHIDONOYL GLYCEROL; CELL DEATH; ENDOCANNABINOIDS; FATTY ACID AMIDE HYDROLASE; HEPATIC STELLATE CELLS; MONOACYLGLYCEROL LIPASE;

AMIDOHYDROLASES; ANIMALS; ARACHIDONIC ACIDS; CELL DEATH; CELLS, CULTURED; CYTOPROTECTION; ENDOCANNABINOIDS; GLYCERIDES; HEPATIC STELLATE CELLS; HEPATOCYTES; MALE; MICE; MICE, INBRED C57BL; MONOACYLGLYCEROL LIPASES; REACTIVE OXYGEN SPECIES;

EID: 84880513441     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.06.033     Document Type: Article

References (35)

1. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258:1946-1949.
2. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
3. Begg M., Pacher P., Batkai S., Osei-Hyiaman D., Offertaler L., Mo F.M., Liu J., Kunos G. Evidence for novel cannabinoid receptors. Pharmacol. Ther. 2005, 106:133-145.
4. Biswas K.K., Sarker K.P., Abeyama K., Kawahara K., Iino S., Otsubo Y., Saigo K., Izumi H., Hashiguchi T., Yamakuchi M., Yamaji K., Endo R., Suzuki K., Imaizumi H., Maruyama I. Membrane cholesterol but not putative receptors mediates anandamide-induced hepatocyte apoptosis. Hepatology 2003, 38:1167-1177.
5. Movsesyan V.A., Stoica B.A., Yakovlev A.G., Knoblach S.M., Lea P.M., Cernak I., Vink R., Faden A.I. Anandamide-induced cell death in primary neuronal cultures: role of calpain and caspase pathways. Cell Death Differ. 2004, 11:1121-1132.
6. Sarker K.P., Maruyama I. Anandamide induces cell death independently of cannabinoid receptors or vanilloid receptor 1: possible involvement of lipid rafts. Cell. Mol. Life Sci. 2003, 60:1200-1208.
7. Siegmund S.V., Uchinami H., Osawa Y., Brenner D.A., Schwabe R.F. Anandamide induces necrosis in primary hepatic stellate cells. Hepatology 2005, 41:1085-1095.
8. Siegmund S.V., Seki E., Osawa Y., Uchinami H., Cravatt B.F., Schwabe R.F. Fatty acid amide hydrolase determines anandamide-induced cell death in the liver. J. Biol. Chem. 2006, 281:10431-10438.
9. Siegmund S.V., Qian T., de Minicis S., Harvey-White J., Kunos G., Vinod K.Y., Hungund B., Schwabe R.F. The endocannabinoid 2-arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species. Faseb J. 2007, 21:2798-2806.
10. Julien B., Grenard P., Teixeira-Clerc F., Van Nhieu J.T., Li L., Karsak M., Zimmer A., Mallat A., Lotersztajn S. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 2005, 128:742-755.
11. Di Marzo V., Bifulco M., De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat. Rev. Drug Discov. 2004, 3:771-784.
12. Di Marzo V., Matias I. Endocannabinoid control of food intake and energy balance. Nat. Neurosci. 2005, 8:585-589.
13. Kathuria S., Gaetani S., Fegley D., Valino F., Duranti A., Tontini A., Mor M., Tarzia G., La Rana G., Calignano A., Giustino A., Tattoli M., Palmery M., Cuomo V., Piomelli D. Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 2003, 9:76-81.
14. Klein T.W. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat. Rev. Immunol. 2005, 5:400-411.
15. Maccarrone M., Finazzi-Agro A. The endocannabinoid system, anandamide and the regulation of mammalian cell apoptosis. Cell Death Differ. 2003, 10:946-955.
16. Osei-Hyiaman D., DePetrillo M., Pacher P., Liu J., Radaeva S., Batkai S., Harvey-White J., Mackie K., Offertaler L., Wang L., Kunos G. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Invest. 2005, 115:1298-1305.
17. Jeong W.I., Osei-Hyiaman D., Park O., Liu J., Batkai S., Mukhopadhyay P., Horiguchi N., Harvey-White J., Marsicano G., Lutz B., Gao B., Kunos G. Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab. 2008, 7:227-235.
18. Wojtalla A., Herweck F., Granzow M., Klein S., Trebicka J., Huss S., Lerner R., Lutz B., Schildberg F.A., Knolle P.A., Sauerbruch T., Singer M.V., Zimmer A., Siegmund S.V. The endocannabinoid N-arachidonoyl dopamine (NADA) selectively induces oxidative stress-mediated cell death in hepatic stellate cells, but not in hepatocytes. Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 302:G873-887.
19. Siegmund S.V., Schwabe R.F. Endocannabinoids and liver disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 294:G357-362.
20. Teixeira-Clerc F., Julien B., Grenard P., Tran Van Nhieu J., Deveaux V., Li L., Serriere-Lanneau V., Ledent C., Mallat A., Lotersztajn S. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat. Med. 2006, 12:671-676.
21. Bataller R., Brenner D.A. Liver fibrosis. J. Clin. Invest. 2005, 115:209-218.
22. Cravatt B.F., Demarest K., Patricelli M.P., Bracey M.H., Giang D.K., Martin B.R., Lichtman A.H. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. USA 2001, 98:9371-9376.
23. Wang L., Liu J., Harvey-White J., Zimmer A., Kunos G. Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Proc. Natl. Acad. Sci. USA 2003, 100:1393-1398.
24. Dinh T.P., Carpenter D., Leslie F.M., Freund T.F., Katona I., Sensi S.L., Kathuria S., Piomelli D. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. USA 2002, 99:10819-10824.
25. Makara J.K., Mor M., Fegley D., Szabo S.I., Kathuria S., Astarita G., Duranti A., Tontini A., Tarzia G., Rivara S., Freund T.F., Piomelli D. Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat. Neurosci. 2005, 8:1139-1141.
26. Bifulco M., Laezza C., Valenti M., Ligresti A., Portella G., Dim V. A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. Faseb J. 2004, 18:1606-1608.
27. Maione S., Bisogno T., de Novellis V., Palazzo E., Cristino L., Valenti M., Petrosino S., Guglielmotti V., Rossi F., Di Marzo V. Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J. Pharmacol. Exp. Ther. 2006, 316:969-982.
28. Goparaju S.K., Ueda N., Yamaguchi H., Yamamoto S. Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Lett. 1998, 422:69-73.
29. Di Marzo V., Maccarrone M. FAAH and anandamide: is 2-AG really the odd one out?. Trends Pharmacol. Sci. 2008, 29:229-233.
30. Blankman J.L., Simon G.M., Cravatt B.F. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem. Biol. 2007, 14:1347-1356.
31. Kozak K.R., Rowlinson S.W., Marnett L.J. Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. J. Biol. Chem. 2000, 275:33744-33749.
32. Gallois C., Habib A., Tao J., Moulin S., Maclouf J., Mallat A., Lotersztajn S. Role of NF-kappaB in the antiproliferative effect of endothelin-1 and tumor necrosis factor-alpha in human hepatic stellate cells. Involvement of cyclooxygenase-2. J. Biol. Chem. 1998, 273:23183-23190.
33. Callejas N.A., Bosca L., Williams C.S., Du B.R., Martin-Sanz P. Regulation of cyclooxygenase 2 expression in hepatocytes by CCAAT/enhancer-binding proteins. Gastroenterology 2000, 119:493-501.
34. Cao Z., Mulvihill M.M., Mukhopadhyay P., Xu H., Erdelyi K., Hao E., Holovac E., Hasko G., Cravatt B.F., Nomura D.K., Pacher P. Monoacylglycerol lipase controls endocannabinoid and eicosanoid signaling and hepatic injury in mice. Gastroenterology 2013, 144:808-817. e815.
35. Taschler U., Radner F.P., Heier C., Schreiber R., Schweiger M., Schoiswohl G., Preiss-Landl K., Jaeger D., Reiter B., Koefeler H.C., Wojciechowski J., Theussl C., Penninger J.M., Lass A., Haemmerle G., Zechner R., Zimmermann R. Monoglyceride lipase deficiency in mice impairs lipolysis and attenuates diet-induced insulin resistance. J. Biol. Chem. 2011, 286:17467-17477.